1726-nm laser treatment for hidradenitis suppurativa (acne inversa)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with bilateral Hurley I–II HS will be randomized in a within-person design so one side receives active 1726‑nm diode laser treatment (AviClear) and the opposite side receives a sham procedure. Participants will undergo three treatment sessions over eight weeks and be followed through Week 24 while remaining on stable HS medications. The primary outcome measures percent change in inflammatory lesion burden from baseline, and an optional translational cohort offers paired 4‑mm punch biopsies at baseline and Week 16. The device targets sebaceous structures in the hair follicle, building on prior laser hair‑removal platforms that reduced HS lesions in controlled trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults 18-60 years; any sex; Fitzpatrick I-VI.
* Clinical HS, Hurley I-II (Investigator confirmed).
* At least one inflammatory nodule in a paired, bilateral region (axilla, groin/inguinal, inframammary, inner thigh, or buttock) within 4 weeks prior to baseline.
* Able to read/speak English/Chinese/Spanish/Vietnamese and sign consent.
* Willing/able to comply with visits, pre/post-care, standardized photography.
* Agree to avoid new HS procedures/therapies in study areas through Week 24.
* No laser contraindication; agrees to shave/clip hair before treatments.
* Optional translational cohort: willing to undergo 4-mm punch biopsy at baseline and Week 16 from the randomized regions (separate consent).

Exclusion Criteria:

* Hurley III (extensive sinus tracts).
* No qualifying nodule(s) in paired bilateral regions in past 4 weeks.
* Prior device/procedure to target areas within 3 months (chemical peel, dermabrasion, microneedling/RF, other lasers/LBB, cryo/chemo-destruction)
* Had Botulinum toxin in target areas within 3 months or planned during study.
* Had systemic retinoid (e.g., isotretinoin) within 3 months.
* Photosensitizing meds that, in PI's judgment, materially increase risk and cannot be held.
* Pregnancy/breastfeeding/plans to conceive during study.
* Active infection, still healing wounds (investigator judgment) in target areas.
* History of keloids/hypertrophic scars, radiation to target areas, malignancy in target areas, diagnosed immunodeficiency, uncontrolled coagulation disorder or therapeutic anticoagulation that cannot be safely managed.
* Excessive tanning or inability to avoid tanning.
* Any condition (medical/mental) or prisoner status that in PI's opinion compromises safety or adherence.

Where it's running

• Wynn Medical Center Rheumatology/Dermatology
  Rosemead, California, United States Recruiting

Study contacts

• Principal investigator: Huynh Wynn Tran CEO/Founder, MD FACP — Wynn Medical Center Research and Education Institute
• Study coordinator: Molynna Nguyen Clinical Research Manager, BS, MA
• Email: molynna.nguyen@wynnmedcenter.com
• Phone: 626 316 8287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

• SPY072 in adults with moderate to severe hidradenitis suppurativa

  This study tests whether SPY072 can help adults with moderate to severe hidradenitis suppurativa when added to their current care, compared with a placebo over 16 weeks.

  Recruiting at 7 sites Phase 2 Spyre Therapeutics, Inc. · Birmingham, Alabama and 33 other locations · NCT07766005

• Brain activity patterns in people with hidradenitis suppurativa and how treatments may relate to changes

  This study tests whether adults with hidradenitis suppurativa show different resting brain activity than healthy people and whether these brain patterns relate to symptoms like pain and mood, and whether they change after 3 months of standard biologic or small-molecule treatment.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07755670

• Roflumilast 0.3% Foam for Hidradenitis Suppurativa in Teens and Adults

  This study tests a topical roflumilast foam to see if it improves HS in adolescents and adults over 16 weeks.

  Recruiting Phase 2 Harrison Dermatology · Missouri City, Texas · NCT07689188

• Global health study on hidradenitis suppurativa

  This study tests how people with hidradenitis suppurativa access care and what treatments they receive across different health systems.

  Recruiting University of Zurich · Zurich · NCT07659769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.